Thalassemia Major Clinical Trial
Official title:
Prospective Crossover Study on Beta(ß)-Thalassaemia Transfusion-dependent to Evaluate the Impact on Transfusion Regimen of Two Pre-storage Leukoreduced PRBCs(In-line Filtration + B-C Separation; Whole Blood Filtration + B-C Conservation)
This study compares the effects of Packed Red Blood Cells (PRBCs) prepared in two different ways on the transfusion indices in beta(ß)-Thalassemia transfusion-dependent patients. The two blood components types derive from the whole blood. In one case, the whole blood is leukoreduced with subsequent plasma removal. In the other case, plasma, buffy coat, and red blood cells (RBCs) are first separated and subsequently, the RBCs leukoreduced. Each type of blood components will be subsequently given to one-half of the patients for a 6-month period and to the other half for other 6-month at the randomization phase, for a total of 12 months of crossed-treatment per patient.
At Day Hospital Talassemia ed Emoglobinopatie of Ferrara, two different PRBCs are available. The two types of blood components are obtained from whole blood, pre-storage leukoreduced and suspended in saline-adenine-glucose-mannitol (SAGM). One method of preparation consists of the whole blood leukoreduction with subsequent plasma removal. The other method first separates plasma, buffy coat, and RBCs, and then the RBCs are leukoreduced. The two methods mainly differ in the final haemoglobin (Hb) content: the Hb level is lower (-13%, approximately) in the second method that also shows the advantage to produce platelets from the buffy coat. A PRBCs unit is not as strictly defined as a therapeutic medication dose (pill or vial): individual PRBCs units may substantially differ in their Hb content, much more than the average difference between the two types of preparations. The aim of this study is to document the extent of the average difference between the two types of preparations, and its impacts on the transfusion indices of ß-Thalassaemia transfusion-dependent patients. All patients will receive each blood component for a period of 6 months (crossover design), for a total of 12 months of transfusion treatment per patient. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02559648 -
Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis
|
Phase 2 | |
Recruiting |
NCT02126046 -
Unrelated Umbilical Cord Blood Following HLA-haploidentical Hematopoietic Stem Cell Transplantation in Patients With β-thalassemia Major
|
N/A | |
Completed |
NCT01125254 -
Amlodipine Use in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major
|
Phase 2/Phase 3 | |
Terminated |
NCT00034528 -
Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia
|
Phase 2 | |
Completed |
NCT00733811 -
Efficacy Study of the Use of Sequential DFP-DFO Versus DFP
|
Phase 4 | |
Enrolling by invitation |
NCT02986698 -
In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM)
|
Phase 1 | |
Not yet recruiting |
NCT06026839 -
Longitudinal Study on the QoL of Pediatric Patients After HSCT and Its Influencing Factors
|
||
Terminated |
NCT00007072 -
Phase II Study of Azacitidine and Phenylbutyrate in Patients With Thalassemia Major
|
Phase 2 | |
Completed |
NCT04292314 -
Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia
|
Phase 2/Phase 3 | |
Completed |
NCT02049450 -
Study of Efficacy and Safety of INC424 in Regularly Transfused Patients With Thalassemia.
|
Phase 2 | |
Active, not recruiting |
NCT04523376 -
Pilot Study PBSCT With TCRab Depletion For Hemoglobinopathies
|
N/A | |
Not yet recruiting |
NCT05777733 -
NAC Effect on Iron Overload and Blood Transfusion in β-thalassemia Major
|
Phase 1 | |
Completed |
NCT01241357 -
High-Tc Susceptometer to Monitor Transfusional Iron Overload
|
Phase 2 | |
Completed |
NCT00749515 -
Pilot Study for Patients With Poor Response to Deferasirox
|
Phase 4 | |
Completed |
NCT04260516 -
The Effect of N-acetylcysteine on Oxidative Stress Status and Iron Overload in Thalassemia Major
|
Phase 1 | |
Recruiting |
NCT02307786 -
Long Term Outcomes in β Thalassemia Major
|
N/A | |
Not yet recruiting |
NCT01323608 -
The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study
|
Phase 4 | |
Completed |
NCT00005893 -
Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders
|
N/A | |
Recruiting |
NCT06137079 -
"Iron Overload and Endocrinological Diseases"
|
||
Completed |
NCT00006138 -
Diagnostic Pilot Study of Dual Energy Absorptiometry in the Detection of Osteopenia or Osteoporosis in Patients With Thalassemia Major
|
N/A |